Consolidated Q1 2026 revenue: KRW 10.55bn (up 3.8% YoY), operating profit of KRW 0.23bn (turnaround from -KRW 1.30bn), net profit of KRW 0.86bn (turnaround from -KRW 1.35bn).
Separate revenue: KRW 0.96bn, operating loss of KRW 0.30bn (improved from -KRW 1.75bn), net profit of KRW 0.89bn (turnaround, driven by dividend income and financial gains).
Acquired 100% stake in new subsidiary MBTV (hydrocolloid patch healthcare business); plans small-scale merger in July 2026.
Issued 11th series convertible bonds worth KRW 2.09bn (conversion price KRW 500, exercisable from Jan 28, 2027 to Dec 27, 2030), used for funding and offsetting acquisition costs.
Decided 2-for-1 stock split (face value from KRW 500 to KRW 1,000), effective April 11, 2026, reducing outstanding shares from 38,355,514 to half.
End of period: consolidated assets KRW 28.89bn, liabilities KRW 13.66bn, equity KRW 15.23bn; accumulated deficit KRW 24.49bn.
Operating cash flow -KRW 1.06bn (improved from -KRW 3.04bn) but still negative.